Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

• Demand and Growth Drivers
  • Biologic therapy approval for EGPA has created a targeted treatment option reducing corticosteroid dependence.
  • Diagnostic accuracy improvement is increasing confirmed case identification and treatment initiation.
  • Clinical experience with anti-IL-5 biologics is expanding prescribing confidence.
• Product and Segment View
  • Biologics are expected to lead with 44.6% of drug class demand in 2026.
  • Intravenous administration is expected to represent 39.8% of route demand.
  • Hospital pharmacies are expected to account for 57.3% of distribution.
• Geography and Competitive Outlook
  • The USA (5.1%) is expected to lead growth through FDA-approved biologic therapy.
  • Japan (4.8%) maintains growth through rheumatology infrastructure and biologic adoption.
  • Companies with EGPA-specific regulatory approvals and anti-IL-5 portfolios are expected to maintain prescribing advantages.
• Analyst Opinion
  • The EGPA treatment market is being transformed by the availability of targeted biologic therapy that reduces reliance on chronic corticosteroid management.
  • Mepolizumab approval has established a new treatment paradigm that improves vasculitis control while reducing steroid-associated adverse effects.
  • The market is benefiting from improved diagnostic accuracy that identifies EGPA patients who benefit from targeted biologic intervention.
  • Companies with established EGPA indication approvals and clinical evidence demonstrating corticosteroid reduction are expected to maintain treatment leadership.

Key Takeaways, Market Size, and Forecast

• The eosinophilic granulomatosis with polyangiitis (EGPA) treatment market was valued at USD 192.3 million in 2025 and is expected to reach USD 201.5 million by the end of 2026.
• The market is projected to grow at a CAGR of 4.8% from 2026 to 2036, reaching USD 322.1 million by 2036.
• The market was valued at USD 192.30 million in 2025.
• By 2036, the market is expected to reach approximately USD 322.07 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 4.8%.
• The market is expected to create an incremental opportunity of USD 120.54 million between 2026 and 2036.
• In 2026, biologics are expected to account for 44.6% of the drug class segment, driven by established clinical efficacy in reducing eosinophil counts, controlling vasculitis flares, and reducing corticosteroid dependence in patients.
• The USA (5.1%) and Japan (4.8%) are among the fastest-growing markets globally.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Definition

The eosinophilic granulomatosis with polyangiitis (EGPA) treatment market covers pharmaceutical interventions used in managing EGPA (formerly Churg-Strauss syndrome), a rare eosinophilic vasculitis affecting small and medium vessels. Treatments include biologics targeting IL-5/IL-5R, corticosteroids, immunosuppressants, and supportive care.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Inclusions

Market scope covers all commercially available EGPA treatments categorized by drug class (biologics, corticosteroids, immunosuppressants, supportive therapies), route of administration (intravenous, subcutaneous, oral), distribution channel (hospital pharmacies, retail pharmacies, specialty pharmacies), and treatment (medication, supportive care, combination therapy). Revenue coverage spans 2026 to 2036.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Exclusions

The scope does not include treatments for other ANCA-associated vasculitides not classified as EGPA, general asthma medications not specifically indicated for EGPA, or diagnostic biopsy services.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with rheumatologists, vasculitis specialists, and hospital pharmacy directors at specialist treatment centres.
• Desk Research: Combined data from vasculitis treatment registries, pharmaceutical prescription databases, and rare disease patient registries.
• Market Sizing and Forecasting: Bottom-up sizing across drug class, route of administration, and distribution channel segments with regional EGPA diagnosis rate curves.
• Data Validation: Cross-checked quarterly against vasculitis registry data, pharmaceutical sales volumes, and specialist treatment centre utilization records.

Why is the Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Growing?

• Regulatory approval of mepolizumab for EGPA has established the first biologic therapy specifically indicated for this condition, creating a targeted treatment option that reduces corticosteroid dependence and vasculitis relapse rates.
• Improving diagnostic accuracy through ANCA testing and eosinophil assessment is increasing confirmed EGPA case identification and driving treatment initiation with targeted biologic therapies.
• Growing clinical experience with anti-IL-5 biologic therapies is expanding prescribing confidence and supporting earlier introduction of targeted treatment in the EGPA management algorithm.

Demand for EGPA treatment reflects the chronic relapsing nature of the disease and the transformative impact of biologic therapy approval on treatment outcomes. EGPA affects approximately 10 to 15 per million adults, with diagnosis often delayed due to the overlap of symptoms with asthma and other eosinophilic conditions. Corticosteroids have historically been the treatment mainstay, but the approval of mepolizumab has created a targeted alternative.

Adoption of biologic therapies leads at 44.6% of drug class demand, driven by the FDA and EMA approval of mepolizumab (Nucala) specifically for EGPA. Mepolizumab targets IL-5 to reduce eosinophil levels, decreasing vasculitis flares and enabling corticosteroid dose reduction in EGPA patients.

Pricing reflects the specialty biologic positioning of anti-IL-5 therapies, with mepolizumab and benralizumab commanding premium pricing. The orphan disease designation supports pricing levels while patient access programs and insurance formulary inclusion address affordability considerations.

Market Segmentation Analysis

• Biologics accounts for 44.6% of the drug class segment.
• Intravenous represents 39.8% of the route of administration segment.
• Hospital Pharmacies leads the distribution channel segment with 57.3% share.

The EGPA treatment market is segmented by drug class, route of administration, distribution channel, and treatment approach. Demand patterns reflect the specialist prescribing environment, the shift toward biologic therapies, and the chronic management requirements that combine targeted treatment with corticosteroid optimization.

Insights into the Biologics Drug Class Segment

Biologics lead at 44.6% driven by the approval of mepolizumab as the first targeted therapy specifically indicated for EGPA. Anti-IL-5 biologics reduce eosinophil-driven vasculitis activity and enable corticosteroid tapering, representing a significant advancement over the previous corticosteroid-dependent management approach.

Insights into the Intravenous Route of Administration Segment

Intravenous administration represents 39.8% of route demand, reflecting the hospital-based administration of biologic therapies and immunosuppressants in specialist vasculitis treatment settings during active disease management.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns.
• Cost and access constraints create segmentation in adoption rates.
• Technology and product development are expanding the addressable market.

The eosinophilic granulomatosis with polyangiitis (egpa) treatment market is shaped by regulatory, technology, and procurement dynamics.

Biologic Therapy Regulatory Approval

Demand is shaped by the regulatory approval of mepolizumab for EGPA, establishing the first targeted biologic treatment for this specific vasculitis and creating a new treatment class within the management algorithm.

Diagnostic Accuracy Improvement

Growth reflects improving ANCA testing and eosinophil assessment that increase confirmed EGPA diagnosis rates, reducing the diagnostic delay that historically limited treatment initiation.

Corticosteroid Reduction Goals

Adoption of biologic therapies is driven by the clinical goal of reducing chronic corticosteroid exposure and its associated adverse effects including osteoporosis, diabetes, and adrenal suppression.

High Per-Patient Biologic Costs

Specialty biologic pricing creates high annual per-patient treatment costs that constrain adoption in budget-limited healthcare systems. Patient access programs and orphan drug frameworks partially address affordability.

Analysis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market By Key Countries

Country	CAGR
USA	5.1%
Japan	4.8%
South Korea	4.7%
UK	4.6%
EU	4.5%

Source: FMI analysis based on primary research and proprietary forecasting model

• USA leads with 5.1% CAGR.
• Japan at 4.8% reflects expanding capabilities.
• South Korea (4.7%) and UK (4.6%) maintain steady growth.

The global eosinophilic granulomatosis with polyangiitis (egpa) treatment market is expected to grow at 4.8% per year from 2026 to 2036.

Demand Outlook for Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market in the United States

The USA is expected to grow at 5.1% through 2036, driven by FDA-approved biologic therapy, established vasculitis treatment centres, and insurance coverage for specialty pharmaceuticals.

• FDA-approved mepolizumab provides targeted EGPA treatment.
• Vasculitis centres deliver specialist prescribing.
• Insurance coverage supports specialty pharmaceutical access.

Future Outlook for Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market in Japan

Japan is expected to grow at 4.8% through 2036, supported by advanced rheumatology infrastructure, biologic therapy adoption, and government rare disease treatment programs.

• Rheumatology infrastructure supports specialist treatment.
• Biologic adoption is increasing in vasculitis management.
• Government programs support rare disease treatment access.

In-depth Analysis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market in South Korea

South Korea is expected to grow at 4.6% through 2036, driven by improving diagnostic capabilities, growing biologic therapy access, and investment in rheumatology treatment infrastructure.

• Diagnostic capabilities support EGPA case identification.
• Biologic therapy access is expanding.
• Rheumatology infrastructure investment improves treatment.

Sales Analysis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market in the United Kingdom

The UK is expected to grow at 4.5% through 2036, supported by NICE-approved mepolizumab for EGPA, NHS specialist commissioning, and vasculitis clinical networks.

• NICE approval enables NHS formulary access for mepolizumab.
• Specialist commissioning supports vasculitis treatment.
• Clinical networks coordinate specialist care delivery.

Opportunity Analysis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market in the European Union

The EU is expected to grow at 4.7% through 2036, supported by EMA-approved biologics, vasculitis research networks, and EU rare disease treatment frameworks.

• EMA-approved biologics enable treatment across member states.
• Vasculitis research networks advance clinical evidence.
• Rare disease frameworks support treatment access.

Competitive Landscape and Strategic Positioning

• GlaxoSmithKline plc leads with an estimated 22.1% market share.
• The competitive landscape includes global and specialized players.
• Entry barriers include regulatory, relationship, and scale factors.

GlaxoSmithKline plc leads the market through Nucala (mepolizumab), the first and most established biologic therapy with specific EGPA regulatory approval in both FDA and EMA jurisdictions.

AstraZeneca plc maintains a position through Fasenra (benralizumab), an anti-IL-5 receptor biologic with clinical investigation in eosinophilic vasculitis conditions including EGPA.

Teva Pharmaceuticals and Sanofi S.A. compete on immunosuppressant and corticosteroid portfolios that form the conventional treatment foundation for EGPA management.

Entry barriers include the orphan disease regulatory pathway requirements, the established position of mepolizumab with EGPA-specific approval, and the small patient population that limits commercial return for new entrants.

Key Companies in the Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

Key global companies leading the eosinophilic granulomatosis with polyangiitis (egpa) treatment market include:

• GlaxoSmithKline plc (UK), AstraZeneca plc (UK), and Sanofi S.A. (France) hold leading positions through anti-IL-5 biologic portfolios and eosinophilic disease treatment experience.
• Teva Pharmaceuticals (Israel) and Regeneron Pharmaceuticals, Inc. (USA) compete on immunosuppressant and biologic portfolios applicable to vasculitis management.
• Amgen Inc. (USA), Roche Holding AG (Switzerland), and Bristol-Myers Squibb (USA) represent emerging positions through immunology pipeline development.

Competitive Benchmarking: Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

Company	EGPA-Specific Approval	Biologic Portfolio	Patient Access Programs	Geographic Reach
GlaxoSmithKline plc	Strong	High	Strong	Global
AstraZeneca plc	Moderate	High	Strong	Global
Teva Pharmaceuticals	Low	Medium	Strong	Global
Sanofi S.A.	Low	High	Strong	Global
Regeneron Pharmaceuticals	Low	Medium	Moderate	N. America, Global
Amgen Inc.	Low	Medium	Moderate	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

• In 2025, GlaxoSmithKline plc continued to support long-term clinical evidence for mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), demonstrating sustained benefits in reducing relapse rates and corticosteroid dependence in patients with eosinophil-driven vasculitis.
• In 2025, AstraZeneca plc continued to advance its IL-5 pathway biologic portfolio, including evaluation of benralizumab across eosinophilic disease indications, with relevance to severe eosinophilic vasculitis and EGPA within broader clinical research programs.

Key Players in the Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market

Major Global Players

• GlaxoSmithKline plc
• AstraZeneca plc
• Teva Pharmaceuticals
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Bristol-Myers Squibb (BMS)
• Allakos Inc.

Emerging Players/Startups

• Amgen Inc.
• Roche Holding AG
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Viela Bio

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 201.53 million to USD 322.07 million, at a CAGR of 4.8%
Market Definition	The eosinophilic granulomatosis with polyangiitis (EGPA) treatment market covers pharmaceutical interventions used in managing EGPA (formerly Churg-Strauss syndrome), a rare eosinophilic vasculitis affecting small and medium vessels. Treatments include biologics targeting IL-5/IL-5R, corticosteroids, immunosuppressants, and supportive care.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	GlaxoSmithKline plc, AstraZeneca plc, Teva Pharmaceuticals, Sanofi S.A., Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb (BMS), Allakos Inc., Roche Holding AG, Celgene Corporation (a Bristol-Myers Squibb company), Novartis AG
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Market Segmented by Drug Class:

• Biologics
• Steroids
• Immunosuppressant
• Immune Globulins

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Market Segmented by Route of Administration:

• Intravenous
• Oral
• Intramuscular

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Market Segmented by Distribution Channel:

• Hospital Pharmacies
• Drug stores
• Retail Pharmacies
• Online Pharmacies

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Market Segmented by Treatment:

• Medication
• Biologic Therapy
• Immunotherapy
• Supportive Care

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. American College of Rheumatology. (2025). ACR/VF Guidelines on ANCA-Associated Vasculitis Management. ACR.
• 2. European League Against Rheumatism. (2024). EULAR Recommendations for EGPA Treatment. EULAR.
• 3. USA Food and Drug Administration. (2025). FDA Approved Drug Products: Mepolizumab for EGPA. FDA.
• 4. Vasculitis Foundation. (2025). VF Treatment Guidelines: Eosinophilic Granulomatosis with Polyangiitis. VF.
• 5. World Health Organization. (2024). WHO Classification of Vasculitis Disorders. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by drug class, route of administration, distribution channel, and treatment.
• Regional and country-level insights across more than 30 markets.
• Biologic therapy clinical evidence and pipeline analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Treatment protocol and corticosteroid reduction analysis.
• Data delivery in PDF and Excel formats.